Through the center, PPD is expected to provide clinical monitoring services to global and local biopharmaceutical companies seeking to develop vaccines in China.
Additionally, the center will help biopharmaceutical companies address requirements for conducting vaccine clinical trials in the country.
Simon Britton, vice president of clinical development for Asia Pacific at PPD, said: “Our strong expertise in vaccine clinical research and large presence in China make us well positioned to help our clients ensure adherence to global standards while addressing unique requirements for monitoring vaccine studies.”